Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TCTDY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AU2020291014A1 IC-16
|
|||||
| Synonyms |
IC-16
Click to Show/Hide
|
|||||
| Organization |
BOLT BIOTHERAPEUTICS, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.74
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through nucleophilic lysines
|
|||||
| Combination Type |
BzL-21
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 1000 nM | |||
| Method Description |
Mycloid TNFa Secretion
|
||||
| In Vitro Model | Mycloid | Mycloid cells | Homo sapiens | ||